Perspective Therapeutics and Merck collaborate on PSV359 + Keytruda for FAP-α solid tumors

Perspective Therapeutics, Inc.

Clinical collaboration with Merck (NYSE: MRK) to evaluate [212Pb]PSV359 plus Keytruda in FAP-α positive solid tumors.
Amendment to ongoing Phase 1/2a study (NCT06710756) in NSCLC and colorectal cancer; first three monotherapy dose cohorts completed enrollment.
Merck supplies pembrolizumab at no cost; Perspective sponsors the study.
FAP-α expressed in majority of solid tumors; combination aims to reshape tumor microenvironment and improve outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.